Lupin Receives U.S. FDA Approval for Amifampridine Tablets
MUMBAI, India and NAPLES, Fla., Nov. 2, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Lupin Receives U.S. FDA Approval for Amifampridine Tablets
PR Newswire
MUMBAI, India and NAPLES, Fla., Nov. 2, 2026
As the First-To-File, Lupin is Eligible for 180-Day Shared Generic Exclusivity
MUMBAI, India and NAPLES, Fla., Nov. 2, 2026 /PRNewswire/ — Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Amifampridine Tablets, 10 mg.
Amifampridine Tablets, 10 mg, are bioequivalent to the reference listed drug (RLD), Firdapse® Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc., for the indication in the approved labeling. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company’s business strategy.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
Firdapse® is the registered trademark of SERB S.A.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lupin-receives-us-fda-approval-for-amifampridine-tablets-302926546.html
SOURCE Lupin Pharmaceuticals, Inc.
